Apogee Therapeutics Common Net Income
| APGE Stock | 62.48 2.40 3.70% |
As of the 5th of February, Apogee Therapeutics shows the Downside Deviation of 3.17, risk adjusted performance of 0.0707, and Mean Deviation of 2.1. Apogee Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apogee Therapeutics maximum drawdown, and the relationship between the information ratio and downside variance to decide if Apogee Therapeutics is priced correctly, providing market reflects its regular price of 62.48 per share. Given that Apogee Therapeutics has jensen alpha of 0.1878, we suggest you to validate Apogee Therapeutics Common's prevailing market performance to make sure the company can sustain itself at a future point.
Apogee Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apogee Therapeutics' valuation are provided below:There are over ninety-three available fundamental signals for Apogee Therapeutics Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Apogee Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 5, 2026, Market Cap is expected to decline to about 1.3 B. In addition to that, Enterprise Value is expected to decline to about 1.2 B This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -163.9 M | -155.7 M | |
| Net Loss | -163.9 M | -155.7 M | |
| Net Loss | (3.80) | (3.98) | |
| Net Income Per E B T | 0.90 | 0.80 |
Apogee | Net Income | Build AI portfolio with Apogee Stock |
Analyzing Apogee Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Apogee Therapeutics's current valuation and future prospects.
Latest Apogee Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Apogee Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Apogee Therapeutics financial statement analysis. It represents the amount of money remaining after all of Apogee Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Apogee Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apogee Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (182.15 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Apogee Net Income Regression Statistics
| Arithmetic Mean | (64,882,484) | |
| Coefficient Of Variation | (77.42) | |
| Mean Deviation | 38,384,387 | |
| Median | (39,785,000) | |
| Standard Deviation | 50,230,073 | |
| Sample Variance | 2523.1T | |
| Range | 142.4M | |
| R-Value | (0.71) | |
| Mean Square Error | 1343.7T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (7,038,700) | |
| Total Sum of Squares | 40369T |
Apogee Net Income History
Other Fundumenentals of Apogee Therapeutics
Apogee Therapeutics Net Income component correlations
Apogee Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Apogee Therapeutics is extremely important. It helps to project a fair market value of Apogee Stock properly, considering its historical fundamentals such as Net Income. Since Apogee Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apogee Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apogee Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Apogee Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apogee Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apogee Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Apogee Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Apogee Therapeutics Common or generate 0.0% return on investment in Apogee Therapeutics over 90 days. Apogee Therapeutics is related to or competes with Centessa Pharmaceuticals, Xenon Pharmaceuticals, Ascentage Pharma, Ultragenyx, Celcuity LLC, Zai Lab, and CG Oncology. Apogee Therapeutics is entity of United States More
Apogee Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apogee Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apogee Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.17 | |||
| Information Ratio | 0.0654 | |||
| Maximum Drawdown | 23.21 | |||
| Value At Risk | (4.18) | |||
| Potential Upside | 4.56 |
Apogee Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apogee Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apogee Therapeutics' standard deviation. In reality, there are many statistical measures that can use Apogee Therapeutics historical prices to predict the future Apogee Therapeutics' volatility.| Risk Adjusted Performance | 0.0707 | |||
| Jensen Alpha | 0.1878 | |||
| Total Risk Alpha | 0.0269 | |||
| Sortino Ratio | 0.0655 | |||
| Treynor Ratio | 0.192 |
Apogee Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0707 | |||
| Market Risk Adjusted Performance | 0.202 | |||
| Mean Deviation | 2.1 | |||
| Semi Deviation | 2.85 | |||
| Downside Deviation | 3.17 | |||
| Coefficient Of Variation | 1166.39 | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.08 | |||
| Information Ratio | 0.0654 | |||
| Jensen Alpha | 0.1878 | |||
| Total Risk Alpha | 0.0269 | |||
| Sortino Ratio | 0.0655 | |||
| Treynor Ratio | 0.192 | |||
| Maximum Drawdown | 23.21 | |||
| Value At Risk | (4.18) | |||
| Potential Upside | 4.56 | |||
| Downside Variance | 10.05 | |||
| Semi Variance | 8.1 | |||
| Expected Short fall | (2.36) | |||
| Skewness | (0.32) | |||
| Kurtosis | 4.74 |
Apogee Therapeutics Backtested Returns
Apogee Therapeutics appears to be very steady, given 3 months investment horizon. Apogee Therapeutics secures Sharpe Ratio (or Efficiency) of 0.1, which signifies that the company had a 0.1 % return per unit of risk over the last 3 months. We have found twenty-six technical indicators for Apogee Therapeutics Common, which you can use to evaluate the volatility of the firm. Please makes use of Apogee Therapeutics' Downside Deviation of 3.17, mean deviation of 2.1, and Risk Adjusted Performance of 0.0707 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apogee Therapeutics holds a performance score of 8. The firm shows a Beta (market volatility) of 1.37, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apogee Therapeutics will likely underperform. Please check Apogee Therapeutics' downside variance, day median price, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether Apogee Therapeutics' price patterns will revert.
Auto-correlation | -0.47 |
Modest reverse predictability
Apogee Therapeutics Common has modest reverse predictability. Overlapping area represents the amount of predictability between Apogee Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apogee Therapeutics price movement. The serial correlation of -0.47 indicates that about 47.0% of current Apogee Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.47 | |
| Spearman Rank Test | -0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 29.67 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Apogee Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Apogee Therapeutics Common reported net income of (182.15 Million). This is 153.37% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 131.9% higher than that of the company.
Apogee Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apogee Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apogee Therapeutics could also be used in its relative valuation, which is a method of valuing Apogee Therapeutics by comparing valuation metrics of similar companies.Apogee Therapeutics is currently under evaluation in net income category among its peers.
Apogee Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apogee Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apogee Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Apogee Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 3.97 B | ||||
| Shares Outstanding | 54.83 M | ||||
| Shares Owned By Insiders | 6.10 % | ||||
| Shares Owned By Institutions | 93.90 % | ||||
| Number Of Shares Shorted | 8.09 M | ||||
| Price To Book | 7.65 X | ||||
| EBITDA | (216.68 M) | ||||
| Net Income | (182.15 M) | ||||
| Total Debt | 11.83 M | ||||
| Book Value Per Share | 9.88 X | ||||
| Cash Flow From Operations | (171.17 M) | ||||
| Short Ratio | 8.06 X | ||||
| Earnings Per Share | (4.38) X | ||||
| Target Price | 104.29 | ||||
| Number Of Employees | 196 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 4.71 B | ||||
| Total Asset | 753.95 M | ||||
| Retained Earnings | (305.92 M) | ||||
| Working Capital | 501.15 M | ||||
| Net Asset | 753.95 M |
About Apogee Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apogee Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apogee Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apogee Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Apogee Therapeutics is a strong investment it is important to analyze Apogee Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics' future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:Check out You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.